Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2− Metastatic Breast Cancer in the Real-World Setting
Most patients did not require a dose modification or interruption with concurrent RT and abemaciclib. These findings suggest that the addition of RT to abemaciclib therapy is well tolerated in patients with HR+, HER2- MBC.
Authors
- ERIKA BRECHTELSBAUER
- Tasneem Lokhandwala (ORCID: https://orcid.org/0000-0002-1983-9557)
- Eileen Farrelly
- Shen Zheng
- Sarah Rybowski
- Holly Martin (ORCID: https://orcid.org/0009-0008-8045-9298)
- Sangmi Kim
- Wambui Gathirua-Mwangi
- Kamran A. Ahmed
Institutions
- Eli Lilly (United States) (US)
- Moffitt Cancer Center (US)
- CSL (United States) (US)
- Macula Vision Research Foundation (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1016/j.adro.2025.101992
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Gilead Sciences
- Moffitt Cancer Center
- Castle Biosciences
- Flatiron Health
- Genentech